Sarcomas | Specialty

Appropriate Patients for Olaratumab + Doxorubicin

November 8th 2016

OS vs PFS with Olaratumab

November 8th 2016

Practical Implications of Using Olaratumab in Patients with STS

November 8th 2016

Registration Trials for Olaratumab and Doxorubicin for STS

November 8th 2016

FDA Approval of Olaratumab + Doxorubicin for STS

November 8th 2016

Multidisciplinary Care of STS

November 8th 2016

Disease State: Advanced Soft Tissue Sarcoma

November 8th 2016

Eribulin Shows Efficacy in Leiomyosarcoma, Further Research Needed

November 3rd 2016

A subgroup analysis from a phase III, open-label, randomized study showed that eribulin had comparable activity to dacarbazine in patients with leiomyosarcoma.

Dr. Elizabeth H. Baldini on Systemic Therapy for Sarcoma

November 2nd 2016

Elizabeth H. Baldini, MD, MPH, director, radiation oncology, center for sarcoma and bone oncology, associate professor of radiation oncology, Harvard Medical School, discusses sarcoma

FDA Approves Olaratumab for Soft Tissue Sarcoma

October 19th 2016

The FDA has granted an accelerated approval olaratumab in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma who are not good candidates for radiotherapy or surgery.

Dr. Jean-Yves Blay on Eribulin in Leiomyosarcoma

October 18th 2016

​Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.

Improved Imaging, Classification Advance Sarcoma Care

October 17th 2016

The field of sarcoma may have reached a turning point, according to Kiran K. Turaga, MD.

Dr. Kiran Turaga on Advancements in Classification, Imaging in Sarcoma

October 13th 2016

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discusses advancements in the field of sarcoma.

Unexpected Benefit Observed From Neoadjuvant Therapy in High-Risk Soft Tissue Sarcoma

October 10th 2016

A technically negative trial in high-risk adult soft tissue sarcoma nonetheless produced a significant survival benefit for anthracycline-based neoadjuvant chemotherapy.

Beyond Imatinib: Expert Explores Next Frontier in GIST

October 6th 2016

Lori Rink, PhD, discusses the groundbreaking impact of imatinib (Gleevec) in gastrointestinal stromal tumors, the heterogeneity of the disease and its impact on personalizing treatment, and emerging therapies in the field.

Expert Says Immunotherapy Not the "Magic Bullet" in Sarcoma

September 29th 2016

Katherine Thornton, MD, discusses the potential that immunotherapy agents could have in the field of sarcoma, as well as the role of genomic profiling in understanding the patients who may benefit from select treatments.

Study Suggests Superiority of Functional Imaging in Assessing Sarcoma Outcomes

September 26th 2016

A comparison of anatomic and functional imaging in the assessment of clinical outcomes in patients with Ewing sarcoma has shown that FDG-PET, assessed by PERCIST criteria, was superior in predicting clinical benefits and identifying responses.

Trabectedin, Eribulin Advance Sarcoma Care in Approved Indications and Beyond

September 24th 2016

Katherine Thornton, MD, discusses the use of trabectedin and eribulin both within and outside of their approved indications for soft tissue sarcoma.

CHMP Adopts Positive Opinion for Olaratumab in Soft Tissue Sarcoma

September 16th 2016

The Committee for Medicinal Products for Human Use has recommended approval of the PDGFRα antagonist olaratumab for use in combination with doxorubicin for patients with advanced soft tissue. sarcoma who are not good candidates for radiotherapy or surgery.

Dr. George D. Demetri on the Importance of Collaboration in Sarcoma

August 25th 2016